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interruptions in tyrosine kinase inhibitor
treatment (resulting from either medica-
tion noncompliance or intolerance).
This study introduces AID and immune
diversificationmechanisms into thealready
complex biology of CML. Future investiga-
tions into the role of AID and BCR-ABL1
in causing tyrosine kinase inhibitor resis-
tance, genomic instability, andprogression
to blast crisis will be important for under-
standing the pathogenesis of the disease
as well as for developing therapeutic inter-
ventions to prevent these processes. Addi-
tional insight is likely to be gained through
investigations into the multilineage dy-
namics of the CML HSC and factors that
regulate expression of PAX5 and AID.
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In this issue of Cancer Cell, Lowy and colleagues show that the SH2 domain of tensin-3 is regulated by phos-
phorylation by Src and that this phosphorylation promotes the oncogenic function of tensin-3. Phosphoryla-
tion of the SH2 domain represents a novel mechanism for the regulation of SH2 ligand binding.Src is a nonreceptor tyrosine kinase that
is activated by a variety of mechanisms
in human cancer. Its biological effects
are mediated by the phosphorylation of a
plethora of protein substrates. A primary
role of tyrosine phosphorylation is to
generate docking sites for proteins con-
taining SH2 or PTB domains, thereby
promoting protein-protein interactions
and the formation of macromolecular
complexes that function in intracellular
signal transduction (Pawson, 2004). The
binding activity of SH2 domains is pri-
marily regulated by the phosphorylation
of the ligand, although some SH2 domain-
target interactions are phosphorylation
independent.
Many prominent Src substrates are
found at focal adhesions, including the
focal adhesion kinase FAK and the Crk-
associated substrate Cas. Focal adhe-
sions are sites of integrin-dependent
substrate adhesion generated by Rho-
ROCK-activated actomyosin-dependent
contractility. They serve as sites for the176 Cancer Cell 16, September 8, 2009 ª20exertion of force on the substratum. They
also serve as sites of intracellular signal
transduction, mediating adhesion-depen-
dent signals that result in anchorage-
dependent cell proliferation.
Tensins are another family of focal
adhesion proteins that can serve as Src
substrates. There are four members of
the family in mammals (Lo, 2004). Tensins
1–3 contain three distinct regions (Fig-
ure 1A): the N-terminal domains bind to
the side of F-actin and target themolecule
to focal adhesions, and the central region
of the tensins is nonconserved, whereas
the C terminus contains an SH2 domain
and a PTB domain. The PTB domain inter-
acts, not with tyrosine phosphorylated
proteins, but with NPXY motifs in the
integrin tails of b1, 3, 5, and 7. Tensin-1
null fibroblasts show migration defects,
and the focal adhesion localization and
SH2 domains of tensin-1 are required
for this promigratory function (Chen
and Lo, 2003). The tensin SH2 domain
binds to tyrosine-phosphorylated Cas09 Elsevier Inc.and FAK, which are pro-oncogenic.
However, it also binds to nonphosphory-
lated RhoGAP7, aka DLC1 (deleted in
liver cancer 1), a focal adhesion-localized
protein that is a known tumor suppressor,
and to the related tumor suppressor DLC3
(Liao et al., 2007; Qian et al., 2007).
Perhaps consistent with the fact that
tensins interact with both pro- and antion-
cogenic proteins, expression profiling and
overexpression studies have supported
both pro- and antioncogenic functions
for tensins. In addition, the oncogenic
functions of tensins may be isoform
specific (Yam et al., 2006; Katz et al.,
2007). Intrigued by this complexity, Qian
et al. (2009) decided to examine the
functions of different tensins in both Src-
transformed fibroblasts and a panel of
human cancer cell lines. Knockdown of
tensin-3 inhibited transformation by Src
and cell migration and growth of the
human cancer lines. These effects were
not observed upon knockdown of the
other tensin family members. In addition,
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Previewsknockdown of tensin-3 reduced the
tumorigenicity of mammary cells derived
from transgenicmice expressing polyoma
middle-T (MMTV-PyMT).
Tensin-1 is known to be tyrosine phos-
phorylated in Src-transformed chicken
embryo fibroblasts (Davis et al., 1991).
Qian et al. observed that in their panel of
human cancer cell lines, the level of phos-
photyrosyl-tensin-3 correlated roughly
both with malignancy and with the level
of Src kinase activity. Furthermore, the
level of phosphotyrosyl-tensin-3 was
strongly reduced by pharmacological
inhibition of Src or by Src siRNA knock-
down. Tensin-3 was also phosphorylated
at tyrosine in the MMTV-PyMT mouse
model, in which endogenous Src is acti-
vated, and this phosphorylation was
reversed by the Src inhibitor PP2. In addi-
tion, recombinant Src could phosphory-
late tensin-3 in vitro. All these and other
observations presented in the paper
argue that tensin-3 is an authentic Src
substrate in mammalian tumor cells.
If tyrosine phosphorylation of tensin-3
is biologically significant, it might be ex-
pected to influence its association with
functionally important partners. Indeed,
inhibition of Src not only decreased the
phosphorylation of two other known Src
substrates, Cas and the RNA-binding
protein Sam68, but also decreased the
level of these two proteins that associated
with tensin-3 in coimmunoprecipitation
assays. This decrease in association
must be due at least in part to decreased
tyrosine phosphorylation of the tensin-3
ligands. In addition, mutational analysis
indicated that three tyrosine residues
in the SH2 domain (Y1173, Y1206, and
Y1256) were, unexpectedly, Src phos-
phorylation sites. Mutation of two of these
residues (2F) or all three (3F) in resulted in
reduced coprecipitation of a GST-SH2
fusion protein with Src, Cas, FAK, and
Sam68. In contrast, however, interaction
of the tensin-3 SH2 domain with two other
ligands, DLC-1 and the integrin-linked
kinase ILK, was unaffected by these
mutations, indicating that the role of these
three tyrosine residues is ligand specific.
Thus, three tyrosine residues in the ten-
sin-3 SH2 domain are phosphorylated by
Src, and the same residues appear to
promote binding to ligands. Putting two
and two together, the most obvious inter-
pretation of these findings is that phos-
phorylation of these residues promotes
binding. Indeed, in both coprecipitation
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Figure 1. Tyrosine Phosphorylation of the SH2 Domain of Tensin-3
(A) Domain structure of tensin-3. In focal adhesions, tensins link integrin heterodimers to the actin cyto-
skeleton. The N terminus of tensin-3 contains domains that bind to F-actin and a focal adhesion targeting
activity. The C terminus contains an SH2 domain and a PTB domain. The PTB domain interacts with NPXY
motifs in the integrin tails of certain b integrins.
(B) Themodel of Qian et al. (2009). The authors propose that binding of ligands to the tensin-3 SH2 domain
is promoted not only by Src-dependent tyrosine phosphorylation of the ligand but also by tyrosine phos-
phorylation of the SH2 domain itself.Cancer Cell 16,and far-western assays, tyrosine phos-
phorylation of the SH2 domain was found
to promote interaction with Src, Cas, and
FAK, as well as with unidentified phos-
photyrosyl-proteins in lysates of Src-
transformed cells. The authors therefore
proposed that phosphorylation of these
residues directly affect ligand binding, as
shown in Figure 1B. This interpretation is
based on homology modeling of the ten-
sin-3 SH2 domain, which suggests that
the two tyrosine residues most signifi-
cantly involved in this regulation are
located close to the ligand-binding site
of the SH2 domain. The binding sites
within the ligands were not defined in
this study, so that it is formally possible
that phosphorylated and nonphosphory-
lated SH2 domains might bind different
phosphotyrosyl sites in their ligands. In
addition, the interaction of tensin-3 with
Src may be mediated in part by the Src
SH2 domain, with the phosphotyrosyl
residues in tensin-3 acting as docking
sites. More detailed biophysical and
structural studies with defined peptide
ligands will be needed to sort this out.
Nevertheless it is clear that the tyrosine
phosphorylation of the tensin-3 SH2
domain is somehow affecting its function,
an observation for which there is no
precedent.
Given these findings, what is the biolog-
ical significance of this novel mode of
regulation? Does the tyrosine phosphory-
lation of the tensin-3 SH2 domain affect
its oncogenic function? Consistent with
this idea, GST fusions containing the
tensin-3 SH2 domain functioned as
dominant-negative mutants in cell migra-
tion and colony growth assays, whereas
the 2F and 3F substitution mutants did
not. Furthermore, overexpression of full-
length tensin-3 promoted cell migration
and colony growth, and this effect was
again abolished by the 2F mutation. As
noted earlier, knockdown of tensin-3
reduced tumorigenicity in the MMTV-
PyMT mouse model. It would be very
interesting to determine whether the
effects of tensin-3 knockdown in this
system could be reversed by wild-type
tensin-3 but not by the 2F or 3F mutant,
as would be predicted by the authors’
model, but this rescue experiment was
not performed.
In summary, although the precise
molecular details remain to be clarified,
Lowy and colleagues have uncoveredSeptember 8, 2009 ª2009 Elsevier Inc. 177
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domain that affects both the biochemical
properties of the SH2 domain and the bio-
logical effects of the molecule in which
it resides. It remains to be determined
whether other SH2 domains are regulated
in a similar manner. The ligand-specificity
of this mode of regulation is intriguing,
given that Src, Cas, and FAK, whose
association with tensin-3 is tyrosine
phosphorylation dependent, are all pro-
oncogenic, whereas the association of
tensin-3 with DLC1, a tumor suppressor,
is not affected by tyrosine phosphoryla-
tion. Thus the biological complexity of
tensin-3 function—oncogenic in someA Molecular Link b
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The protein kinase AKT is frequent
chemotherapy. In this issue of Can
the phosphatase PHLPP. This regu
Despite increased interest in targeted
therapeutics, cytotoxic chemicals remain
the front-line defense against malignant
tumors. However, malignant tumors vary
greatly in their response to chemothera-
peutic agents. A compound might elicit
a strong apoptotic response in one tumor
but have little to no effect on another.
Furthermore, tumors initially sensitive to
treatment can develop resistance to
specific classes of agents or, in some
instances, develop a more generalized
chemoresistance to a large variety of
agents with distinct modes of action.
Therefore, there has been much interest
in defining molecular mechanisms un-
derlying this differential response and
identifying markers to predict response.
A hallmark of cellular transformation is
evasion from apoptotic stimuli, and
oncogenic pathways promoting aberrant
cell survival can also affect the general
178 Cancer Cell 16, September 8, 2009 ª20contexts, antioncogenic in others—may
reflect not only the complexity of the
targets to which it binds but also the
complexity of its regulation.
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AKT (also known as PKB) is a critical
survival kinase that is normally activated
in a growth-factor-dependent manner but
is constitutively activated at a high
frequency in tumors through oncogenic
events affecting its upstream regulation
(Engelman et al., 2006). The most impor-
tant upstream activators of AKT are the
class I phosphoinositide 3-kinases (PI3K),
which generate the lipid second mes-
sengerphosphatidylinositol-3,4,5-trisphos-
phate (PIP3). PI3K lipid products bind
directly to the pleckstrin homology (PH)
domain of AKT, thereby recruiting AKT to
the plasma membrane where it is subse-
quently activated (see below). Therefore,
the activation status of PI3K and the
levels of its lipid products are the key
factors dictating the level of AKT activity
in a cell. PTEN is a lipid phosphatase that
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s been implicated in resistance to
negatively regulates AKT through
chemosensitivity in cancer cells.
removes the critical 3-phosphate from
PIP3, thereby reversing PI3K signaling
and blocking AKT activation. Importantly,
PTEN is encoded by a tumor-suppressor
gene that is frequently mutated in human
cancers, and thesemutations are the likely
cause of aberrant AKT activation in many
tumors. Activating mutations and amplifi-
cations affecting the gene encoding the
p110a isoform of PI3K (PIK3CA) are also
common in cancers. Furthermore, other
common oncogene products, such as
Ras, receptor tyrosine kinases (e.g.,
EGFR, HER2, c-Met), and fusion proteins
(e.g., BCR-Abl), are all potent activators of
PI3K that lead to increasedAKT activation.
The large number of oncogenes and tumor
suppressors upstream of AKT results in
aberrantlyelevated levelsofAKTactivation
in the majority of sporadic cancers.
Full activation of AKT requires phos-
phorylation on two highly conserved
